Bipolar affective disorder (BPAD) is a common psychiatric disorder with complex genetic aetiology. We have undertaken a genome-wide scan in one of the largest samples of bipolar affected sibling pairs (ASPs) using a two-stage approach combining sample splitting and marker grid tightening. In this second stage analysis, we have examined 17 regions that achieved a nominally significant maximum likelihood LOD score (MLS) threshold of 0.74 (or 1.18 for the X-chromosome) in stage one. The second stage has added 135 ASP families to bring the total stage 2 sample to 395 ASPs. In total, 494 microsatellite markers have been used to screen the human genome at a density of 10 cM in the first stage sample (260 ASPs) and 5 cM in the second stage. Under the broad diagnostic model, two markers gave LOD scores exceeding 3 with two-point analysis: D4S392 (LOD ¼ 3.30) and D10S197 (LOD ¼ 3.18). Multipoint analysis demonstrated suggestive evidence of linkage between BPAD and chromosomal regions 6q16-q21 (MLS ¼ 2.61) and 4q12-q21 (MLS ¼ 2.38). 6q16-q21 is of particular interest because our data, together with those from two recent genome scans, make this the best supported linkage region in BPAD. Further, our data show evidence of a gender effect at this locus with increased sharing predominantly within the male-male pairs. Our scan also provides support for linkage (MLSZ1.5) at several other regions that have been implicated in meta-analyses of bipolar disorder and/or schizophrenia including 9p21, 10p14-p12 and 18q22. Molecular Psychiatry (2005) 10, 831-841.
Bipolar affective disorder (Bipolar Disorder; manic depressive illness; BPAD; MIM 125480) has a lifetime prevalence of approximately 1% and is characterised by disturbances in mood ranging from extreme elation or mania to severe depression. 1 Family, twin and adoption studies provide evidence that genetic factors are important in determining susceptibility and molecular genetic studies are ongoing. 2, 3 While single genes may play a major role in a few families, the inheritance of most BPAD is consistent with the action of both multiple genes and environmental factors. 4 Although the pattern of findings emerging from systematic genome screens in BPAD is consistent with there being no gene of major effect to explain the majority of cases of bipolar disorder, several regions have been implicated repeatedly as shown by metaanalyses, 5, 6 including regions of 9p, 10q, 14q, 13q, 22q and chromosome 18. The linkage findings to date for bipolar disorder are less consistent than those for schizophrenia 7 and this is likely to be due, at least in part, to the substantially smaller number of families studied in bipolar disorder. 6, 8 Here we present the results of a large, two-stage systematic genome scan of bipolar disorder that includes 395 affected sibling pairs (ASPs). Our study, the Wellcome Trust UK-Irish bipolar affective disorder sibling pair genome screen, is a collaboration between MGs group at Trinity College Dublin (Republic of Ireland) and NCs groups at the University of Cardiff (Wales) and University of Birmingham (England). Our sample of bipolar ASPs is one of the largest reported to date, exceeded in magnitude only by the NIMH Wave 3 sample. 9 The methodology follows the two-stage paradigm, 10 which incorporates both sample splitting and marker grid tightening. Our first stage sample, comprising 258 ASPs that were genotyped at a density of approximately 10 cM, identified 17 discontinuous regions of the human genome that met criteria for follow-up in stage 2. 11 Here, we present the results of the completed genome scan in which we examined each of the stage 1 regions of interest at an average resolution of 4.8 cM in an enlarged total sample of 395 ASPs.
Materials and methods

Sample description
The additional families and individuals within the full stage 2 sample were collected using identical ascertainment criteria and methodology to those used in our stage 1 sample. 11 Nuclear families were ascertained in which the proband met the DSM-IV 12 criteria for Bipolar I disorder (BPI), and at least one other sibling met the criteria for BPI, Schizoaffective Bipolar disorder (SA-BP), Bipolar II disorder (BPII), Bipolar disorder not otherwise specified (BP-NOS) or Recurrent Major Depressive Disorder (MDD-R). Families were recruited in the Republic of Ireland and United Kingdom through their respective mental health services, patient support groups and articles in the national media. Subjects from all, save three of these families, were Caucasian Europeans. The mean age of onset of mood disorder for the 464 BPI individuals was 24.9 years (SD ¼ 9.1 years), and the mean age at interview of all affected sibs was 47.3 years (SD ¼ 15.3 years). Details of the composition of the total sample set are described in Table 1 . The full stage 2 sample is closely similar to the stage 1 sample in terms of pedigree sizes, gender distribution, distribution of diagnoses and characteristics of illness. The composition of the additional sample (ie that added to the stage 1 sample to form the full stage 2 sample) is as follows: DSM-IV diagnoses of additional genotyped individuals: BPI: 176; BPII: 9; SA-BP: 4; BP-NOS: 4; MDD-R: 21.
Following receipt of multicentre research ethics approval, written informed consent was obtained from all participating individuals. Participants were interviewed by trained investigators using a semistructured research interview (Schedule for Clinical Assessment in Neuropsychiatry; SCAN; 13 ) and case note information was obtained. Lifetime best estimate psychiatric diagnoses were made according to DSM-IV criteria by two independent raters using all available information. Any case where there was disagreement was rated by a third investigator and discussed to reach a consensus. Regular meetings were held between all interviewers and raters in order to maximise clinical consistency and reliability. Interrater reliability was assessed using clinical data from 20 cases (chosen to represent a typical cross-section of subjects recruited within the study), which were rated by each investigator and compared against consensus to obtain individual k coefficients of reliability.
14 Diagnostic reliability was shown to be excellent with a mean k of 0.88.
Each affected sibling pair was classified into one of three diagnostic models. The three nested diagnostic models were as follows: Narrow including BPI individuals only, Intermediate which included BPI, BPII and SA-BP, and the Broad diagnostic model which included, additional to those in the intermediate category, individuals with BP-NOS and those with MDD-R. The stage 2 sample, detailed in Table 1 , ). Markers typed only in stage 2 consisted of tandem repeated di-, tri and tetranucleotides selected on the basis of location. Details of stage 2 markers used are available on request. Where markers were not included in the Marshfield map (http://research.marshfieldclinic.org/ genetics/), intermarker distance and order were deduced using the observed data with CRI-MAP 16 supplemented by the CEPH and DeCode marker data from the MAP-O-MAT v1.1b database. 17 Whole blood cell extraction, DNA quantification and amplification were performed using methods described previously. 11 Post-PCR, amplicons from individual multiplex reactions were pooled in empirically determined ratios, and resolved on 4% denaturing polyacrylamide gels (Long Ranger, FMC Bioproducts, Rockford, ME, USA) with electrophoreses performed using an ABI-377XL genetic analyser. Gel images were analysed using GENESCAN version 3.1 and GENOTYPER version 2.5 software (Applied Biosystems, Ltd). An adapted version of the MEGA-BASE database 18 was used to store all phenotype and extracted genotype data. This application was used to perform 'allele binning', conduct preliminary checks for inheritance incompatibilities and facilitate the production of LINKAGE format files to be used in subsequent analyses.
Statistical analyses
Linkage analyses Genotypic data underwent assessment for Mendelian inheritance incompatibilities using PEDCHECK. 19 Family structures were tested with RELATIVE, 20 
RELCHECK
21,22 and PREST. 23 In addition, GRR 24 and in-house software was used to check for monozygotic twins and relationships between individuals in different pedigrees. Where inconsistencies were detected that could not be resolved, the relevant individual was removed from subsequent analysis. Allele frequencies were estimated from the observed data with SPLINK, which was also used to undertake two-point linkage analyses. 25, 26 Multipoint affected sib pair linkage analyses were undertaken using MAPMAKER/SIBS 27 for X-chromosome data and GENEHUNTER version 2.1 28 for autosomal data. In both cases, the software was used to estimate the allele sharing derived maximum likelihood LOD score (MLS) (restricted to the 'possible triangle') at centiMorgan (cM) intervals across chromosomes included in the follow-up study. 'All possible pairs (unweighted)' were included in the analyses. (Thus, we used GENEHUNTER for MLS analyses, not NPL analyses.) We examined the effect of gender of affected sibling as a covariate on our linkage findings using the logistic regression framework of Rice et al 29 and modified by Holmans.
30
Estimate of genome-wide significance A two-stage simulation process was implemented to evaluate genome-wide levels of statistical significance for the study. 31 Under the null hypothesis of no linkage and no linkage disequilibrium (LD) between genetic markers, a two-stage genome scan was simulated, maintaining the same marker informativity, family structure and missing data as in the observed data set. Under this procedure, linkage signals detected in stage 1 under a narrow diagnosis of BP, that met the stage 2 criteria, 11 were mapped at a finer resolution and in an extended sample of pedigrees. The whole of the genome was then analysed under the three affection models (narrow, intermediate and broad). Where simulated regions were followed up in stage 2, in the absence of observed marker data at a fine resolution, pseudomarkers with four equifrequent alleles (heterozygosity of 0.75) were generated. A full two-stage genome scan was simulated 1000 times and the suggestive and significant levels estimated, given the three nonindependent affection models analysed.
Power
To estimate the power of the stage 2 sample to detect linkage, simulated replicates under the alternative hypothesis of linkage were used to estimate the probabilities that MLS values exceeded 2.0 and 3.0. The replicate samples were identical to that of the stage 2 collection in terms of pedigree structure and availability of DNA. A 10 cM intermarker distance was simulated for 400 microsatellite markers (each with five equifrequent alleles and heterozygosity of 0.80). Four distinct measures of genetic effect were modelled by evaluating a locus-specific recurrence risk in siblings (l S ) of 1.25, 1.5, 2 and 3, for a disease locus placed at a position most difficult to detect (ie midway between two flanking markers).
Results
A total of 198 markers were genotyped for 887 individuals in the total stage 2 sample. The mean heterozygosity and polymorphism information content (PIC) of the markers were 0.78 and 0.75, respectively. The average intermarker distance in follow-up regions was 4.8 cM and the average information content of follow-up regions was 0.79. The mean success rate for genotyping in the follow-up regions was 92.4%. We identified two individuals as being potential half rather than full-siblings, and two potential full rather half siblings, as had been recorded at time of ascertainment. In addition to the nine potential MZ twins or sample mix-ups identified in stage 1, a further two were identified in the additional pedigrees included in stage 2. These potential MZ twins and full/half sibling inconsistencies were removed from the analysis. Marker order was confirmed using the CRI-MAP application. We detected a single marker that had mistakenly been labelled incorrectly, and hence positioned on the marker map incorrectly. Once this marker was relabelled and repositioned, all chromosomes were congruent with published map orders and lengths. As genotyping was performed blind to the pedigree structure, the potential MZ twins allowed us to obtain an estimate of genotyping error rate of 1%. Quality control procedures and estimated error rate were similar between the stage 1 and stage 2 analyses.
Using two-point analysis, we identified two markers that gave LOD scores exceeding 3 D4S392 (4q12-q21; LOD ¼ 3.30) and D10S197 (10p12; LOD ¼ 3.18), both under the broad diagnostic model (see Table 2 ). The two-point signal at D4S392 receives support from surrounding markers and the multipoint analysis (see below). The two-point signal at D10S197 is not supported by the immediately adjacent markers and the multipoint analysis shows MLSo1 at the location of his marker. Multipoint ASP analyses in the total stage 2 data set demonstrated five regions showing MLS41.5. These were 2q37-2qter, 4q12-q21, 6q16-q21, 9p21-p12 and 10p14-p12 (see Table 2 ). Of these regions, two met the criteria 31 for genome-wide suggestive linkage-namely 6q16-q21 (MLS ¼ 2.61) and 4q12-q21 (MLS ¼ 2.38). An estimate of the genespecific effect size of the putative locus identified in this region on 6q16-q21 was a l S of approximately 1.13. In the analysis with gender of affected sibling as a covariate the only region of interest where the LOD score was substantially increased was on 6q16-q21 (LOD increase ¼ 2.53; P ¼ 0.013). At this locus, the increased allele sharing was present mainly within the male-male pairs (IBD ¼ 0.70, compared with IBD ¼ 0.55 in female-female pairs and 0.48 in malefemale pairs).
Simulations
Simulation analysis of the stage 2 sample showed that under the null hypothesis of no linkage an MLS of 1.33 or greater was expected to occur in all three diagnostic models less than once per genome scan. This approximates to the genome-wide suggestive level of linkage in a specific diagnostic model. 31 Simulation data have also shown that the MLS value for genome-wide significant linkage (ie once per 20 genome-wide scans; 31 ) was an MLS of 2.57 if present in all diagnostic models. (If considering only the maximum value under any of the three diagnostic models irrespective of the values observed under the other models, the genome-wide significant level corresponds to MLSZ3.65 and the genome-wide suggestive level to MLSZ2.27.)
Power
The expected MLS ¼ 6.14 for l S ¼ 3, MLS ¼ 3.81 for l S ¼ 2, MLS ¼ 2.27 for l S ¼ 1.5, MLS ¼ 1.44 for l S ¼ 1.25, corresponding to a power to detect such effect sizes at MLS43 (MLS42) of 94% (99%), 60% (80%), 25% (51%) and 7% (22%), respectively.
Discussion
Within the second stage of the Wellcome Trust UKIrish BPAD sibling-pair genome scan, we have used DNA from an expanded sample of 395 ASPs (all possible pairs, under the broad diagnostic model) to follow up the 17 regions identified in our stage 1 analyses 11 by typing microsatellite markers at an average density of 5 cM. No region met statistical criteria for genome-wide significance. However, two regions met criteria corresponding to the genomewide suggestive linkage category 31 (ie expected to occur no more than once per genome scan under the null hypothesis)-these were at chromosome 6q16-21 (MLS ¼ 2.61; 112 cM) and chromosome 4q12-q21 (MLS ¼ 2.38; 82 cM). Several other regions had MLS 41 ( Table 2 ). The highest MLS narrow diagnostic model scores in stage 2 analyses were found on chromosome 9p21-12 (MLS ¼ 1.74; 53 cM) and at 4q12-q21 (MLS ¼ 1.82; 77 cM).
The completed two-stage genome scan did not detect a locus of major effect. This is consistent with our own first-stage findings and with other genomewide scans in BPAD 6 and with mathematical modelling of complex disorders in general. 4, 32 The largest estimated effect size was a locus-specific relative risk, l S ¼ 1.13 in our region of interest on chromosome 6q.
Chromosome 6q16-q21
This was the most interesting region supported in our study. Substantially increased support for this region was found in moving to stage 2 from stage 1 of our 30 we found that taking account of gender as a covariate within our linkage analyses resulted in a substantial increase of LOD score at the peak of this region (LOD increase ¼ 2.53; P ¼ 0.013). At this locus, the increased allele sharing was present mainly within the malemale pairs (IBD ¼ 0.70, compared with IBD ¼ 0.55 in female-female pairs and 0.48 in male-female pairs). These findings suggest the possibility of a gender effect at this locus but this has not previously been reported and requires replication in other samples that show linkage in this region.
This region was not implicated in the two metaanalyses to date of bipolar disorder 5, 6 but has received strong support from two subsequent reports. 9, 33 In a study of 250 families comprising wave 3 of the NIMH collaborative study, 9 support was found for linkage between markers in this region of 6q and BPAD that met criteria for genome-wide suggestive evidence (maximum multipoint LOD ¼ 2.2). As with our current study, the NIMH group reported strongest linkage evidence under the broadest diagnostic model. Recently, a more detailed analysis of chromosome 6 linkage data conducted on the NIMH sample identified a significant positive correlation between LOD scores in this region of 6q and a region of 6p. 34 Further, this analysis found that, conditional upon evidence of linkage to 6p there was a large increase in 6q linkage at 113.4 cM between D6S474 and D6S1021. We also found a significant positive correlation between LOD score in these same two regions (Spearman's rank correlation r ¼ 0.157; P ¼ 0.014 (two-tailed)). However, in our data we found that marker-marker linkage was present that extended from our region of interest at 6q to include the region used as a covariate by Schulze et al. 34 We conclude that these regions cannot be considered independent (as was assumed in the analysis of Schulze) and that the most parsimonious explanation for the observed correlation is a reflection of linkage. In a sample of 25 pedigrees of Portuguese origin 33 and using highdensity SNP mapping methodology, genome-wide significant evidence for linkage at 6q22 (physical location 127 Mb) with a maximum NPL ¼ 4.2 have been reported. This refined the linkage at D6S1021 detected in their earlier microsatellite linkage analyses in these pedigrees. 33, 35 Support for linkage between markers in the vicinity of D6S1021 and BPAD was also reported by others.
36,37
The LOD-1 interval in our data is defined by the markers q-terminal of D6S300 to p-terminal of D6S268 (an interval of B10 cM and B13 Mb). This region contains several genes of potential interest as candidates in the pathogenesis of bipolar disorder. Of particular interest is the observation that the microsatellite marker at the peak of our signal, D6S1021 (104.71 Mb) is within B1 Mb of the PREP locus (105.77 Mb). This locus encodes prolyl endopeptidase (EC 3.4.21.26), a large cytosolic enzyme involved in the maturation and degradation of peptide hormones and neuropeptides that has been implicated in the pathogenesis of mood disorders. Plasma concentrations of PREP have been reported to be abnormal in patients with affective disorders-levels are elevated in manic phase, but decreased during unipolar and bipolar depression. 38, 39 As the effect of antidepressant and antimanic medication restores prolyl endopeptidase activity to normal levels, 39 it has been suggested that prolyl endopeptidase may be involved in regulating inositol metabolism in mammalian cells. 40, 41 Further, in a Dictyostelium discoideum model Williams et al 40 have found evidence that DpoA (the PREP homologue) may be important in the mechanisms of action of mood stabilisers used in the management of bipolar disorder. This gene warrants analysis as a positional and functional candidate for BPAD. Other genes within this region that merit mention as plausible candidates include GRIK2 (glutamate receptor 6 isoform 2 precursor), SLT (G protein-coupled receptor slt), GPR63 (G proteincoupled receptor 63) and ACT (activator of cAMPresponsive element modulator).
Chromosome 4q12-q21
Substantially increased support for this region was found in moving to stage 2 from stage 1 of our study (the best multipoint score in the first stage was MLS ¼ 1.3 under the intermediate model 11 ). Results for the stage 2 analysis show the highest narrow diagnostic model MLS of 1.82, immediately distal to marker D4S392 (70.77 Mb) with MLS score of 2.24 and 2.26 under the intermediate and broad models, respectively. We note that our signal in this region is not unimodal and may be the result or more than one distinct susceptibility locus in this broad region. This region has not been implicated in the previous metaanalyses of bipolar disorder or schizophrenia. 5, 6 A signal has been reported at 4q21 in a LD study of Costa Rican bipolar individuals (marker D4S395-at physical position 84 Mb). The LOD-1 interval in our data extends from q-terminal of D4S398 to p-terminal of D4S2964 (an interval of B15 cM and B19 Mb). A potentially interesting candidate within this interval is EPHA5 ephrin receptor locus (66.19 Mb), one of the family of receptors implicated in modification of the strength of existing synapses. 42 Eph receptors play key roles in diverse functions such as ensuring developing axons establish contact with intended targets, signal potentiation in the synaptic cleft, and in the formation of memory. 42 , 43 Murai and Pasquale The MLS data were generated using GENEHUNTER version 2.1 for autosomes and MAPMAKER/SIBS for the X-chromosome. have noted that genes for ephrin-A1, -A3, -A4, -A5 and -B2 are all in chromosomal regions that have been linked to schizophrenia, and that ephrin-B2, located on 13q33, represents a plausible candidate for BPAD. [45] [46] [47] [48] [49] [50] [51] Several of the other regions producing MLS approximately equal to or exceeding 1.5 in our study have been implicated within meta-analyses of bipolar and/or schizophrenia genome scans. ) indicates the highest ranked genetic bin from D9S1869 to D9S1853 as providing suggestive evidence (P ¼ 0.006) of linkage to BPAD. This 'bin' overlaps directly with the region implicated in our analysis.
10p14-p12-The p-terminal linkage signal at D10S547 is in the region of chromosome 10 ranked 12th in the recent BPAD meta-analysis, 6 and also implicated by the schizophrenia meta-analysis. 7 There have been several reported linkages in both BPAD and schizophrenia that directly overlap with the stage 2 linkage signals. 52 Given that this linkage finding appears to be reported in both functional psychoses, it is possible that a susceptibility locus common to schizophrenia and BPAD may exist in this region. We note that our maximal two-point LOD score in this chromosome 10 region lies at the extreme centromeric end of the region of interest and is not supported by flanking markers. We are, therefore, cautious in attaching undue weight to this specific LOD score finding relative to the more modest but consistent multipoint signal in the central part of the region of interest.
18q22-This distal 18q region has received support in GSMA meta-analyses of both bipolar disorder 6 and schizophrenia. 7 Simulation studies suggest that this study had a power in excess of 94% to detect a susceptibility locus of l S 43 for the narrow model at MLS ¼ 3. However, even with 395 sib pairs (a published bipolar sibling pair sample size exceeded only by the NIMH Wave 3; 9 ), our power at MLS ¼ 3 to detect effect sizes of l S ¼ 2, 1.5, 1.25 was only 60%, 25%, 7%, respectively. Our sample has a subsantial proportion of parents that were not available for genotyping which, of course, has a negative influence on power. However, even with complete parental genotype information, the power would still be modest to detect small to moderate effect sizes-for example, under this ideal situation the power of our sample at MLS ¼ 3 to detect an effect size of l S ¼ 1.25 would be only 18%. This issue regarding the power of most studies to date in the face of likely modest effect sizes in bipolar disorder 4 may explain the variation in findings between studies. Use of larger samples (B600 to 800 nuclear families) will be required to detect, in a reliable manner, the expected susceptibility genes of modest effect size. A further approach that can offer improved recovery of linkage information from an existing clinical sample is use of a higher density linkage map-this has been shown to be particularly advantageous in samples where there is substantial missing parental data, as is often the case with large data sets of adult onset diseases, including our own bipolar sample. 53 For several of the regions that were examined only in stage 1 in our study, we extracted only approximately 50% of the linkage information (see Figure 1) . The recent improvement in available map densities and genotyping technologies provide opportunities for improving power. 53 A further approach that may extract additional information from an existing data set is use of analyses sensitive to clinical subtypes and covariates (such as age at onset or presence of psychosis). In future investigations, we propose to use all of these approaches-sample enhancement, denser mapping and phenotypic refinement-to maximise our power for genetic dissection of the bipolar phenotype.
In summary, using a sample of 395 bipolar ASPs we have found suggestive evidence of linkage between BPAD and two regions of the human genome. Chromosome 6q16-q21 is of particular interest because this region has also been implicated in recent genome scans of US pedigrees 9 and Portuguese pedigrees. 33 Our data show evidence of a gender effect with increased sharing predominantly within the male-male pairs. This is a novel observation and requires replication in other data sets showing linkage to 6q. The other suggestive region was 4q12-q21. Our scan also provides support for linkage at other regions that have been implicated in meta-analyses of bipolar disorder and/or schizophrenia including 9p21, 10p14-p12 and 18q22. Our findings suggest loci of modest effect with the largest estimated locus-specific effect size being 1.13.
